Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

MRD negativity in MM patients correlates with improved survival, suggesting its potential as a surrogate marker for survival outcomes. Novel therapeutics complicate the assessment of PFS and OS, ...

Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers. Minimal residual disease, or MRD, ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

A few months back, good news hit the multiple myeloma community: the U.S. Food & Drug Administration voted to accept a new endpoint — MRD, or measurable residual disease — for accelerated approval of ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...